Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adultsand children

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 2, 2014, Pages 253-262.e2

  Yang, Zhuo ^a   Clark, Nick ^a   Park, K T ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Colonoscopy; Cost effectiveness; Crohn's disease; Endoscopy; Fecal calprotectin; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CALGRANULIN;

ADULT; ARTICLE; CHILD; COLONOSCOPY; COMPUTER PROGRAM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENDOSCOPIC BIOPSY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FECES ANALYSIS; GASTROINTESTINAL ENDOSCOPY; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; SCREENING; SENSITIVITY AND SPECIFICITY;

CD; COLONOSCOPY; COST-EFFECTIVENESS; CROHN'S DISEASE; DEE; DIRECT ENDOSCOPIC EVALUATION; ENDOSCOPY; FC; FCS; FECAL CALPROTECTIN; FECAL CALPROTECTIN SCREENING; IBD; ICER; INCREMENTAL COST-EFFECTIVENESS RATIO; INFLAMMATORY BOWEL DISEASE; PROBABILISTIC SENSITIVITY ANALYSIS; PSA; QALY; QUALITY-ADJUSTED LIFE YEAR; UC; ULCERATIVE COLITIS; WILLINGNESS TO PAY; WTP;

ADULT; CHILD; COLITIS, ULCERATIVE; COLONOSCOPY; COST-BENEFIT ANALYSIS; CROHN DISEASE; DECISION TREES; ENDOSCOPY, GASTROINTESTINAL; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MASS SCREENING; SENSITIVITY AND SPECIFICITY;

EID: 84892480511     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.06.028     Document Type: Article

References (21)

1. Ing C., DiMaggio C., Whitehouse A., et al. Long-term differences in language and cognitive function after childhood exposure to anesthesia. Pediatrics 2012, 130:e476-e485.
2. Limburg P.J., Devens M.E., Harrington J.J., et al. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003, 98:2299-2305.
3. Carroccio A., Iacono G., Cottone M., et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003, 49(Pt 1):861-867.
4. Diamanti A., Panetta F., Basso M.S., et al. Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm Bowel Dis 2010, 16:1926-1930.
5. Schoepfer A.M., Beglinger C., Straumann A., et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009, 15:1851-1858.
6. Quail M.A., Russell R.K., Van Limbergen J.E., et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:756-759.
7. Steinbakk M., Naess-Andresen C.F., Lingaas E., et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990, 336:763-765.
8. Røseth A.G., Fagerhol M.K., Aadland E., et al. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol 1992, 27:793-798.
9. van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010, 341:c3369.
10. Dubinsky M.C., Johanson J.F., Seidman E.G., et al. Suspected inflammatory bowel disease: the clinical and economic impact of competing diagnostic strategies. Am J Gastroenterol 2002, 97:2333-2342.
11. Henderson P., Wilson D.C. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2013, May 14. Epub ahead of print.
12. CPT 2012: standard edition 2011, American Medical Association, American Medical Association, Chicago, IL.
13. Centers for Medicare & Medicaid Services Medicare Fee-for-Service Payment, 2012. Available at: Accessed September 1, 2012. http://www.cms.gov/Medicare/Medicare.html.
14. Kok L., Witteman B.J., Goedhard J.G., et al. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study. Clin Chem 2013, 58:989-998.
15. Mindemark M. Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012, 45:552.
16. Rufo P.A., Denson L.A., Sylvester F.A., et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. JPediatr Gastroenterol Nutr 2012, 55:93-108.
17. Heuschkel R., Salvestrini C., Beattie R.M., et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:839-849.
18. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791-794.
19. Tengs T.O., Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000, 38:583-637.
20. Allen E., Nicolaidis C., Helfand M. The evaluation of rectal bleeding in adults: a cost-effectiveness analysis comparing four diagnostic strategies. J Gen Intern Med 2005, 20:81-90.
21. Grosse S.D. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008, 8:165-178.